Bolt Biotherapeutics, Inc. (NASDAQ:BOLT – Get Free Report) was the recipient of a significant increase in short interest in June. As of June 15th, there was short interest totaling 27,250 shares, an increase of 107.6% from the May 31st total of 13,125 shares. Currently, 1.6% of the company’s stock are short sold. Based on an average daily volume of 24,781 shares, the short-interest ratio is presently 1.1 days.
Bolt Biotherapeutics Stock Performance
BOLT traded up $0.04 on Wednesday, reaching $3.90. The company had a trading volume of 19,322 shares, compared to its average volume of 27,242. The company has a quick ratio of 3.51, a current ratio of 3.51 and a debt-to-equity ratio of 0.98. Bolt Biotherapeutics has a 1 year low of $3.75 and a 1 year high of $7.20. The stock has a market capitalization of $7.48 million, a PE ratio of -0.24 and a beta of 1.12. The stock has a 50-day moving average price of $4.68 and a 200-day moving average price of $5.00.
Bolt Biotherapeutics (NASDAQ:BOLT – Get Free Report) last posted its earnings results on Tuesday, May 12th. The company reported ($4.31) earnings per share for the quarter, missing the consensus estimate of ($2.85) by ($1.46). The firm had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $1.50 million. Bolt Biotherapeutics had a negative net margin of 455.15% and a negative return on equity of 100.89%. As a group, research analysts forecast that Bolt Biotherapeutics will post -11.1 EPS for the current fiscal year.
Institutional Investors Weigh In On Bolt Biotherapeutics
Wall Street Analyst Weigh In
A number of analysts have weighed in on BOLT shares. Rodman & Renshaw started coverage on Bolt Biotherapeutics in a research note on Thursday, May 28th. They issued a “buy” rating and a $22.00 price target on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research report on Monday, April 20th. Finally, HC Wainwright restated a “buy” rating and set a $7.00 target price on shares of Bolt Biotherapeutics in a research note on Thursday, May 28th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $34.67.
View Our Latest Report on Bolt Biotherapeutics
About Bolt Biotherapeutics
Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.
Featured Stories
- Five stocks we like better than Bolt Biotherapeutics
- Hershey Stock May Be Near a Sweet Spot as Cocoa Pressure Eases
- Comcast’s NBCUniversal Split Puts Broadband Back in Focus
- 3 European Stocks to Carry Investors Through the Back Half of 2026
- Ouster Is Breaking Out as a Physical AI Leader: Here’s What’s Driving the Move
Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
